TY - JOUR
T1 - Circadian serum progesterone variations on the day of frozen embryo transfer in artificially prepared cycles
AU - Loreti, Sara
AU - Roelens, Caroline
AU - Drakopoulos, Panagiotis
AU - De Munck, Neelke
AU - Tournaye, Herman
AU - Mackens, Shari
AU - Blockeel, Christophe
N1 - Funding Information:
The authors thank the women who voluntarily participated and the staff of Brussels IVF, Brussels, Belgium. C.B. S.M. C.R. and S.L. are responsible for the concept and study design and for manuscript writing. S.L. performed the data collection and drafted the manuscript. P.D. performed the statistical and data analyses. H.T. and N.D.M. revised the manuscript critically for important intellectual content. All authors contributed to the interpretation, discussion and editing of the manuscript. All the authors approved the final version.
Publisher Copyright:
© 2023 Reproductive Healthcare Ltd.
PY - 2024/1
Y1 - 2024/1
N2 - Research question: What is the intra-day variation of serum progesterone related to vaginal progesterone administration on the day of frozen embryo transfer (FET) in an artificial cycle? Design: A prospective cohort study was conducted including 22 patients undergoing a single blastocyst artificial cycle (AC)–FET from August to December 2022. Endometrial preparation was achieved by administering oestradiol valerate (2 mg three times daily) and consecutively micronized vaginal progesterone (MVP; 400 mg twice daily). A blastocyst FET was performed on the 6th day of MVP administration. Serum progesterone concentrations were measured on the day of transfer at 08:00, 12:00, 16:00 and 20:00 hours. The first and last blood samples were collected just before MVP was administered. Results: The mean age and body mass index of the study population were 33.95 ± 3.98 years and 23.10 ± 1.95 kg/m2. The mean P-values at 08:00, 12:00, 16:00 and 20:00 hours were 11.72 ± 4.99, 13.59 ± 6.33, 10.23 ± 3.81 and 9.28 ± 3.09 ng/ml, respectively. A significant decline, of 2.41 ng/ml (95% confidence interval 0.81–4.00), was found between the first and last progesterone measurements. Conclusion: A statistically significant intra-day variation of serum progesterone concentrations on the day of FET in artificially prepared cycles was observed. This highlights the importance of a standardized procedure for the timing of progesterone measurement on the day of AC–FET. Of note, the study results are applicable only to women using MVP for luteal phase support; therefore it is necessary to confirm its validity in comparison with the different existing administration routes of progesterone.
AB - Research question: What is the intra-day variation of serum progesterone related to vaginal progesterone administration on the day of frozen embryo transfer (FET) in an artificial cycle? Design: A prospective cohort study was conducted including 22 patients undergoing a single blastocyst artificial cycle (AC)–FET from August to December 2022. Endometrial preparation was achieved by administering oestradiol valerate (2 mg three times daily) and consecutively micronized vaginal progesterone (MVP; 400 mg twice daily). A blastocyst FET was performed on the 6th day of MVP administration. Serum progesterone concentrations were measured on the day of transfer at 08:00, 12:00, 16:00 and 20:00 hours. The first and last blood samples were collected just before MVP was administered. Results: The mean age and body mass index of the study population were 33.95 ± 3.98 years and 23.10 ± 1.95 kg/m2. The mean P-values at 08:00, 12:00, 16:00 and 20:00 hours were 11.72 ± 4.99, 13.59 ± 6.33, 10.23 ± 3.81 and 9.28 ± 3.09 ng/ml, respectively. A significant decline, of 2.41 ng/ml (95% confidence interval 0.81–4.00), was found between the first and last progesterone measurements. Conclusion: A statistically significant intra-day variation of serum progesterone concentrations on the day of FET in artificially prepared cycles was observed. This highlights the importance of a standardized procedure for the timing of progesterone measurement on the day of AC–FET. Of note, the study results are applicable only to women using MVP for luteal phase support; therefore it is necessary to confirm its validity in comparison with the different existing administration routes of progesterone.
KW - Artificial cycle
KW - Circadian variation
KW - Frozen embryo transfer
KW - Serum progesterone
UR - https://www.mendeley.com/catalogue/9136d143-9d20-356c-aad7-95a1cc78c57b/
UR - http://www.scopus.com/inward/record.url?scp=85177844944&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.rbmo.2023.103601
DO - https://doi.org/10.1016/j.rbmo.2023.103601
M3 - Article
C2 - 37992522
VL - 48
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
SN - 1472-6483
IS - 1
M1 - 103601
ER -